A Randomised Double-blind Two-period Crossover Study to Investigate the Effect of Treatment With Repeat Doses of a PPAR Gamma Agonist on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma Compared With Repeat Doses of Placebo
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2007 Status changed from in progress.
- 06 Nov 2006 New trial record.